Infliximab for 6 months added on combination therapy in early rheumatoid arthritis – 2-year results from an investigator-initiated, randomised, double-blind, placebo-controlled study (the NEO-RACo Study)



: 2-year results from an investigator-initiated, randomised, double-blind, placebo-controlled study (the NEO-RACo Study)

: Leirisalo-Repo M, Kautiainen H, Laasonen L, Korpela M, Kauppi MJ, Kaipiainen-Seppanen O, Luosujarvi R, Luukkainen R, Karjalainen A, Blafield H, Uutela T, Ilva K, Julkunen HA, Paimela L, Puolakka K, Moilanen E, Hannonen PJ, Mottonen T

Publisher: BMJ PUBLISHING GROUP

: 2013

: Annals of the Rheumatic Diseases

: ANNALS OF THE RHEUMATIC DISEASES

: ANN RHEUM DIS

: 6

: 72

: 6

: 851

: 857

: 7

: 0003-4967

DOI: https://doi.org/10.1136/annrheumdis-2012-201365


Conclusions Most patients with early active RA achieve clinical remission and develop negligible joint damage with the intensified FIN-RACo regimen. Adding INFL for the first 6 months delays radiological progression.



Last updated on 2024-26-11 at 20:52